XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 104 filers reported holding XENON PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $854,000 | -11.3% | 25,000 | 0.0% | 0.13% | -6.5% |
Q2 2023 | $962,500 | +7.6% | 25,000 | 0.0% | 0.14% | +0.7% |
Q1 2023 | $894,750 | -9.2% | 25,000 | 0.0% | 0.14% | -13.8% |
Q4 2022 | $985,750 | +9.2% | 25,000 | 0.0% | 0.16% | +3.2% |
Q3 2022 | $903,000 | +18.7% | 25,000 | 0.0% | 0.16% | +25.0% |
Q2 2022 | $761,000 | -0.4% | 25,000 | 0.0% | 0.12% | +20.4% |
Q1 2022 | $764,000 | -2.2% | 25,000 | 0.0% | 0.10% | +5.1% |
Q4 2021 | $781,000 | +104.5% | 25,000 | 0.0% | 0.10% | +88.5% |
Q3 2021 | $382,000 | -18.0% | 25,000 | 0.0% | 0.05% | -16.1% |
Q2 2021 | $466,000 | +4.0% | 25,000 | 0.0% | 0.06% | -3.1% |
Q1 2021 | $448,000 | +16.4% | 25,000 | 0.0% | 0.06% | +8.5% |
Q4 2020 | $385,000 | +39.0% | 25,000 | 0.0% | 0.06% | +18.0% |
Q3 2020 | $277,000 | -11.8% | 25,000 | 0.0% | 0.05% | -15.3% |
Q2 2020 | $314,000 | +10.6% | 25,000 | 0.0% | 0.06% | -9.2% |
Q1 2020 | $284,000 | -13.4% | 25,000 | 0.0% | 0.06% | +16.1% |
Q4 2019 | $328,000 | +45.8% | 25,000 | 0.0% | 0.06% | +36.6% |
Q3 2019 | $225,000 | -8.9% | 25,000 | 0.0% | 0.04% | -6.8% |
Q2 2019 | $247,000 | -2.8% | 25,000 | 0.0% | 0.04% | -4.3% |
Q1 2019 | $254,000 | +60.8% | 25,000 | 0.0% | 0.05% | +39.4% |
Q4 2018 | $158,000 | -52.1% | 25,000 | 0.0% | 0.03% | -41.1% |
Q3 2018 | $330,000 | -28.3% | 25,000 | -50.0% | 0.06% | -31.7% |
Q2 2018 | $460,000 | +369.4% | 50,000 | +150.0% | 0.08% | +382.4% |
Q1 2018 | $98,000 | +71.9% | 20,000 | 0.0% | 0.02% | +70.0% |
Q4 2017 | $57,000 | -3.4% | 20,000 | 0.0% | 0.01% | -9.1% |
Q3 2017 | $59,000 | -6.3% | 20,000 | 0.0% | 0.01% | -8.3% |
Q2 2017 | $63,000 | -21.2% | 20,000 | 0.0% | 0.01% | -20.0% |
Q1 2017 | $80,000 | -48.1% | 20,000 | 0.0% | 0.02% | -51.6% |
Q4 2016 | $154,000 | -4.9% | 20,000 | 0.0% | 0.03% | -8.8% |
Q3 2016 | $162,000 | +37.3% | 20,000 | 0.0% | 0.03% | +36.0% |
Q2 2016 | $118,000 | -17.5% | 20,000 | 0.0% | 0.02% | -16.7% |
Q1 2016 | $143,000 | -11.2% | 20,000 | 0.0% | 0.03% | -9.1% |
Q4 2015 | $161,000 | -2.4% | 20,000 | 0.0% | 0.03% | -8.3% |
Q3 2015 | $165,000 | -28.6% | 20,000 | 0.0% | 0.04% | -20.0% |
Q2 2015 | $231,000 | – | 20,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |